From: Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Characteristic | Basal-like | ERBB2 | Luminal A | Luminal B | Normal-like | p |
---|---|---|---|---|---|---|
n = 59 | n = 43 | n = 122 | n = 54 | n = 91 | ||
Cohort (n) | 0.51e | |||||
Stockholm | 25 | 15 | 39 | 23 | 37 | |
Uppsala | 34 | 28 | 83 | 31 | 54 | |
Mean age at breast cancer diagnosis | 54 | 59 | 66 | 61 | 59 | <0.001e |
Menopausal status (%) | 0.0807e | |||||
Premenopausal | 27.5 | 13.3 | 10.9 | 24.4 | 18.6 | |
Postmenopausal | 72.5 | 86.7 | 89.1 | 75.6 | 78.6 | |
Mean tumor size (mm) | 22.9 | 27.9 | 21.8 | 22.6 | 20.7 | 0.0345f |
Tumor size < 21 mm (%) | 51 | 35 | 57 | 42 | 70 | <0.001e |
Elston grade | <0.001e | |||||
I | 3.5 | 4.8 | 34.5 | 5.7 | 43.2 | |
II | 21.1 | 38.1 | 54.3 | 39.6 | 52.3 | |
III | 75.4 | 57.1 | 11.2 | 54.7 | 4.5 | |
p53 mutation (%)a | 64.7 | 39.3 | 9.6 | 38.7 | 3.7 | <0.001e |
HRT (%)b | <0.001e | |||||
Never | 60.0 | 78.6 | 81.6 | 82.6 | 48.6 | |
Former | 8.0 | 7.1 | 13.2 | 8.7 | 0.0 | |
Ongoing | 32.0 | 14.3 | 5.3 | 8.7 | 51.4 | |
Lymph-positive (%) | 29 | 48 | 33 | 41 | 33 | 0.312e |
Estrogen receptor positive (%) | 45.8 | 67.4 | 97.5 | 87.0 | 92.3 | <0.001e |
Progesterone receptor positive (%) | 54.2 | 72.1 | 93.2 | 77.8 | 92.3 | <0.001e |
Genomically unstable (%)b | 76.0 | 78.6 | 56.4 | 78.3 | 37.1 | 0.0031e |
Genomic instability by ploidyb | 0.0123e | |||||
Diploid stable | 12.0 | 7.1 | 25.6 | 4.3 | 40.0 | |
Diploid unstable | 4.0 | 0.0 | 20.5 | 26.1 | 17.1 | |
Tetraploid stable | 4.0 | 7.1 | 7.7 | 8.7 | 8.6 | |
Tetraploid unstable | 16.0 | 7.1 | 12.8 | 13.0 | 0.0 | |
Aneuploid stable | 8.0 | 7.1 | 10.3 | 8.7 | 14.3 | |
Aneuploid unstable | 56.0 | 71.4 | 23.1 | 39.1 | 20.0 | |
Treatment type (%)c | 0.0353e | |||||
None | 39.7 | 35.7 | 43.3 | 35.8 | 46.2 | |
Endocrine | 36.2 | 45.2 | 50.8 | 56.6 | 44.0 | |
Chemotherapy | 15.5 | 16.7 | 5.0 | 5.7 | 7.7 | |
Radiotherapy | 8.6 | 2.4 | 0.8 | 1.9 | 2.2 | |
Breast cancer event within 5 years (%)d | 30 | 51 | 17 | 43 | 19 | <0.001e |